Positively charged amphiphilic chitosan derivative for the transscleral delivery of rapamycin

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 13, 2012, Pages 8105-8111

  Elsaid, Naba ^a   Jackson, Timothy L ^b,c   Gunic, Mirza ^a   Somavarapu, Satyanarayana ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOPHILE; CHITOSAN DERIVATIVE; O OCTANOYL CHITOSAN POLYETHYLENE GLYCOL; RAPAMYCIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CRITICAL MICELLE CONCENTRATION; DIFFERENTIAL SCANNING CALORIMETRY; DIFFUSION COEFFICIENT; DRUG SOLUBILITY; INFRARED SPECTROSCOPY; LASER DOPPLER FLOWMETRY; LIGHT SCATTERING; MEMBRANE TRANSPORT; MORPHOLOGY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SCLERA; SPECTROFLUOROMETRY; TRANSMISSION ELECTRON MICROSCOPY; X RAY POWDER DIFFRACTION; ZETA POTENTIAL;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOCOMPATIBLE MATERIALS; CALORIMETRY, DIFFERENTIAL SCANNING; CHITOSAN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG DELIVERY SYSTEMS; LASER-DOPPLER FLOWMETRY; LIGHT; MICELLES; POLYETHYLENE GLYCOLS; SCATTERING, RADIATION; SCLERA; SIROLIMUS; SPECTROMETRY, FLUORESCENCE; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURFACE-ACTIVE AGENTS; SUS SCROFA; X-RAY DIFFRACTION;

EID: 84873375793     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10717     Document Type: Article

References (50)

1. Sehgal SN, Baker H, Vézina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo). 1975;28:727-732.
2. Martel RR, Klicius J, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol. 1977;55:48-51.
3. Houchens DP, Ovejera AA, Riblet SM, Slagel DE. Human brain tumor xenografts in nude mice as a chemotherapy model. Eur J Cancer Clin Oncol. 1983;19:799-805.
4. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8:128-135.
5. Simamora P, Alvarez JM, Yalkowsky SH. Solubilization of rapamycin. Int J Pharm. 2001;213:25-29.
6. Buech G, Bertelmann E, Pleyer U, Siebenbrodt I, Borchert HH. Formulation of sirolimus eye drops and corneal permeation studies. J Ocul Pharmacol Ther. 2007;23:292-303.
7. Lin WJ, Juang LW, Lin CC. Stability and release performance of a series of pegylated copolymeric micelles. Pharm Res. 2003; 20:668-673.
8. Hämäläinen KM, Kananen K, Auriola S, Kontturi K, Urtti A. Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. Invest Ophthalmol Vis Sci. 1997;38:627-634.
9. Dunlevy JR, Rada JA. Interaction of lumican with aggrecan in the aging human sclera. Invest Ophthalmol Vis Sci. 2004;45: 3849-3856.
10. Aliabadi HM, Shahin M, Brocks DR, Lavasanifar A. Disposition of drugs in block copolymer micelle delivery systems: from discovery to recovery. Clin Pharmacokinet. 2008;47:619-634.
11. Schipper NG, Olsson S, Hoogstraate JA, deBoer AG, Varum KM, Artursson P. Chitosans as absorption enhancers for poorly absorbable drugs 2: mechanism of absorption enhancement. Pharm Res. 1997;14:923-929.
12. Schoendwald RD. Ocular pharmacokinetics. In: Textbook of Ocular Pharmacology. Zimmerman TJ, ed. Philadelphia, PA: Lippincott-Raven; 1997:119-138.
13. Dodane Y, Amin Khan M, Merwin JR. Effect of chitosan on epithelial permeability and structure. Int J Pharm. 1999;182: 21-32.
14. Sogias IA, Williams AC, Khutoryanskiy VV. Why is chitosan mucoadhesive? Biomacromolecules. 2008;9:1837-1842.
15. Yen M, Yang J, Mau J. Antioxidant properties of chitosan from crab shells. Carbohyd Polym. 2008;74:840-844.
16. Xu Y, Wen Z, Xu Z. Chitosan nanoparticles inhibit the growth of human hepatocellular carcinoma xenografts through an antiangiogenic mechanism. Anticancer Res. 2009;29:5103-5109.
17. Mizumura Y, Matsumura Y, Hamaguchi T, et al. Cisplatinincorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity. Jpn J Cancer Res. 2001;92:328-336.
18. Yoo HS, Park TG. Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer. J Control Release. 2001;70:63-70.
19. Huang Y, Yu H, Guo L, Huang Q. Structure and self-assembly properties of a new chitosan-based amphiphile. J Phys Chem B. 2010;114:7719-7726.
20. Wei Z, Hao J, Yuan S, et al. Paclitaxel-loaded Pluronic P123/ F127 mixed polymeric micelles: formulation, optimization and in vitro characterization. Int J Pharm. 2009;376:176-185.
21. Slager TL, Prozonic FM. Simple methods for calibrating IR in TGA/IR analyses. Thermochimica Acta. 2005;426:93-99.
22. Olsen TW, Sanderson S, Feng X, Hubbard WC. Porcine sclera: thickness and surface area. Invest Ophthalmol Vis Sci. 2002; 43:2529-2532.
23. Nicoli S, Ferrari G, Quarta M, et al. Porcine sclera as a model of human sclera for in vitro transport experiments: histology, SEM, and comparative permeability. Mol Vis. 2009;15:259-266.
24. Kundaiker S, Hussain AA, Marshall J. Component characteristics of the vectorial transport system for taurine in isolated bovine retinal pigment epithelium. J Physiol. 1996;492:505-516.
25. Jackson TL, Hussain A, Hodgetts A, et al. Human scleral hydraulic conductivity: age-related changes, topographical variation, and potential scleral outflow facility. Invest Ophthalmol Vis Sci. 2006;47:4942-4946.
26. Yáñez JA, Forrest ML, Ohgami Y, Kwon GS, Davies NM. Pharmacometrics and delivery of novel nanoformulated PEG-bpoly(epsilon-caprolactone) micelles of rapamycin. Cancer Chemother Pharmacol. 2008;61:133-144.
27. Ruedaa DR, Secalla T, Bayerb RK. Differences in the interaction of water with starch and chitosan films as revealed by infrared spectroscopy and differential scanning calorimetry. Carbohydr Polym. 1999;40:49-56.
28. Netoa CGT, Giacomettib JA, Jobb AE, Ferreirab FC, Fonsecaa JLC, Pereira MR. Thermal analysis of chitosan based networks. Carbohydr Polym. 2005;62:97-103.
29. Deng L, Qi H, Yao C, Feng M, Dong A. Investigation on the properties of methoxy poly(ethylene glycol)/chitosan graft copolymers. J Biomater Sci Polym Ed. 2007;18:1575-1589.
30. Rouf MA, Vural I, Bilensoy E, Hincal A, Erol DD. Rapamycincyclodextrin complexation: improved solubility and dissolution rate. J Inclusion Phenom Mac Chem. 2011;70:167-175.
31. Ricciutelli M, Di Martino P, Barboni L, Martelli S. Evaluation of rapamycin chemical stability in volatile-organic solvents by HPLC. J Pharm Biomed Anal. 2006;41:1070-1074.
32. Tang B, Yang Z, Zhang S. Poly(polyethylene glycol methyl ether methacrylate) as novel solid-solid phase change material for thermal energy storage. J Appl Polym Sci. 2012;125:1377-1381.
33. Ghaffari A, Navaee K, Oskoui M, Bayati K, Rafiee-Tehrani M. Preparation and characterization of free mixed-film of pectin/ chitosan/Eudragit RS intended for sigmoidal drug delivery. Eur J Pharm Biopharm. 2007;67:175-186.
34. Preethama AC, Satisha CS. Formulation of a poorly watersoluble drug sirolimus in solid dispersions to improve dissolution. J Dispersion Sci Technol. 2011;32:778-783.
35. Swindells DCN, White PS, Findlay JA. The x-ray crystal structure of rapamycin, C51H79NO13. Can J Chem. 1978; 56:2491-2492.
36. Liu L, Li F, Fang Y, Guo S. Regioselective grafting of poly(ethylene glycol) onto chitosan and the properties of the resulting copolymers. Macromol Biosci. 2006;6:855-861.
37. Casettari L, Vllasaliub D, Castagninoa E, Stolnikb S, Howdlec S, Illum L. PEGylated chitosan derivatives: synthesis, characterizations and pharmaceutical applications. Prog Polym Sci. 2012;37:659-685.
38. Kwon GS, Forrest ML, Inventors. Wisconsin Alumni Research Foundation, assignee. Micelle composition of polymer and passenger drug. US Patent No. 20060251710. April 11, 2006.
39. Lu W, Li F, Mahato RI. Poly(ethylene glycol)-block-poly(2-methyl-2-benzoxycarbonyl-propylene carbonate) micelles for rapamycin delivery: in vitro characterization and biodistribution. J Pharm Sci. 2011;100:2418-2429.
40. Pepić I, Filipović-Grčić J, Jalšenjak I. Interactions in a nonionic surfactant and chitosan mixtures. Colloids Surf A Physicochem Eng Asp. 2008;327:95-102.
41. Bakshi MS, Sachar S, Yoshimura T, Esumi K. Association behavior of poly(ethylene oxide)-poly(propylene oxide)-poly(-ethylene oxide) block copolymers with cationic surfactants in aqueous solution. Colloid Interface Sci. 2004;278:224-233.
42. Davis SS, Illum L. Polymeric microspheres as drug carriers. Biomaterials. 1988;9:111-115.
43. Valls R, Vega E, Garcia ML, Egea MA, Valls JO. Transcorneal permeation in a corneal device of non-steroidal anti-inflammatory drugs in drug delivery systems. Open Med Chem J. 2008;2:66-71.
44. Forrest ML, Won CY, Malick AW, Kwon GS. In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-bpoly(epsilon-caprolactone) micelles. J Control Release. 2006; 110:370-377.
45. Cooper ER, Kleinman DM, Nivaggioli T, Dor PJM, Mudumba S, Inventors. Transscleral delivery. US patent 20120034279. February 8, 2012.
46. Wang Z, Do CW, Avila MY, Stone RA, Jacobson KA, Civan MM. Barrier qualities of the mouse eye to topically applied drugs. Exp Eye Res. 2007;85:105-112.
47. Conquet P, Durand G, Laillier J, Plazonnet B. Evaluation of ocular irritation in the rabbit: objective versus subjective assessment. Toxicol Appl Pharmacol. 1977;39:129-139.
48. Alonso MJ, Sánchez A. The potential of chitosan in ocular drug delivery. J Pharm Pharmacol. 2003;55:1451-1463.
49. Enríquez de Salamanca A, Diebold Y, Calonge M, et al. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance. Invest Ophthalmol Vis Sci. 2006;1416-1425.
50. Pade V, Stavchansky S. Estimation of the relative contribution of the transcellular and paracellular pathway to the transport of passively absorbed drugs in the Caco-2 cell culture model. Pharm Res. 1997;14:1210-1215.